Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Africa Gazette.
Press releases published on April 30, 2025
Facet Power and PAMOL Plantations Sign MOU to Support Climate Resilience, Food Security, and Economic Growth in Cameroon
EIN Presswire
·
April 30, 2025
Catalyzing climate-positive innovation, natural capital and community regeneration, and inclusive opportunities for climate prosperity. WILMINGTON, DE, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- In a landmark partnership, Facet Power, Inc., a …
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
GlobeNewswire
·
April 30, 2025
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
UPDATE -- Burgundy Diamond Mines reports first quarter 2025 results
GlobeNewswire
·
April 30, 2025
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines Limited (ASX:BDM) (Burgundy or the Company) provided the filing of its financial and operating results for the first quarter (Q1-2025) ended March 31, 2025, to the Australian Stock …
Burgundy Diamond Mines reports first quarter 2025 results
GlobeNewswire
·
April 30, 2025
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines Limited (ASX:BDM) (Burgundy or the Company) provided the filing of its financial and operating results for the first quarter (Q1-2025) ended March 31, 2025, to the Australian Stock …
Unibit Solutions Digital Marketing Announces Francois Muscat Named WSI’s Q1 Top Contributor
GlobeNewswire
·
April 30, 2025
George, South Africa, April 30, 2025 (GLOBE NEWSWIRE) -- Unibit Solutions Digital Marketing, a leading digital marketing production center, announces that Francois Muscat, a valued WSI franchisee and owner of Unibit Solutions Digital Marketing, has been …
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
GlobeNewswire
·
April 30, 2025
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME) IL-13Rα2 is overexpressed by some of the most “ …
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced …
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
GlobeNewswire
·
April 30, 2025
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on …
Integral Metals Reports Preliminary Geomicrobial Results from Burntwood Project, Highlights Biological Pathfinder Potential for REE Exploration
GlobeNewswire
·
April 30, 2025
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce preliminary results from its 2024 geomicrobial survey at the Burntwood Project in northern …
Global Uranium Advances Athabasca Basin Exploration with Launch of ZTEM Survey at Astro Project
GlobeNewswire
·
April 30, 2025
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the "Company" or “Global”) and Cosa Resources Corp. (TSX-V: COSA) (OTCQB: COSAF) (FSE: SSKU) (“Cosa”) are pleased to announce that geophysical …
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
April 30, 2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus …
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire
·
April 30, 2025
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire
·
April 30, 2025
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that …
Altimmune to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …
Stallion Uranium Announces Completion of Ground Gravity Survey over Coyote Target
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce the successful completion of a ground gravity survey over its Coyote Target, …
InflaRx to Report First Quarter 2025 Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire
·
April 30, 2025
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, …
Emerita Files NI 43-101 Technical Report for the IBW Project, Marking a 35% Increase in Total Indicated Resources and a 44% Increase in Total Inferred Resources
GlobeNewswire
·
April 30, 2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports that it has filed the independent NI 43-101 compliant technical report for its Iberian Belt West Project (“IBW” …
XORTX Provides Update on FDA Type B Meeting Request
GlobeNewswire
·
April 30, 2025
● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …